Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Samuel Tekeste Workenhe"'
Autor:
Shayla Grace Verburg, Rebecca Margaret Lelievre, Michael James Westerveld, Jordon Marcus Inkol, Yi Lin Sun, Samuel Tekeste Workenhe
Publikováno v:
PLoS Pathogens, Vol 18, Iss 8, p e1010718 (2022)
Viruses are ubiquitous intracellular genetic parasites that heavily rely on the infected cell to complete their replication life cycle. This dependency on the host machinery forces viruses to modulate a variety of cellular processes including cell su
Externí odkaz:
https://doaj.org/article/2cdfd35547074984a387e81fe5b53790
Autor:
Tushar Dhawan, Muhammad Atif Zahoor, Nishant Heryani, Samuel Tekeste Workenhe, Aisha Nazli, Charu Kaushic
Publikováno v:
Viruses, Vol 13, Iss 1, p 70 (2021)
Herpes simplex virus type 2 (HSV-2) is the primary cause of genital herpes which results in significant morbidity and mortality, especially in women, worldwide. HSV-2 is transmitted primarily through infection of epithelial cells at skin and mucosal
Externí odkaz:
https://doaj.org/article/10e794423f8a433981ceec51ea666dda
Autor:
Chadi Zakaria, Polen Sean, Huy-Dung Hoang, Louis-Phillipe Leroux, Margaret Watson, Samuel Tekeste Workenhe, Jaclyn Hearnden, Dana Pearl, Vinh Tai Truong, Nathaniel Robichaud, Akiko Yanagiya, Soroush Tahmasebi, Seyed Mehdi Jafarnejad, Jian-Jun Jia, Adrian Pelin, Jean-Simon Diallo, Fabrice Le Boeuf, John Cameron Bell, Karen Louise Mossman, Tyson Ernst Graber, Maritza Jaramillo, Nahum Sonenberg, Tommy Alain
Publikováno v:
PLoS Pathogens, Vol 14, Iss 8, p e1007264 (2018)
Herpes Simplex Virus 1 (HSV1) is amongst the most clinically advanced oncolytic virus platforms. However, efficient and sustained viral replication within tumours is limiting. Rapamycin can stimulate HSV1 replication in cancer cells, but active-site
Externí odkaz:
https://doaj.org/article/513a554b6c4d453d9e82ff6357c01efc
Autor:
Nader El-Sayes, Alyssa Vito, Omar Salem, Samuel Tekeste Workenhe, Yonghong Wan, Karen Mossman
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 1754, p 1754 (2022)
International Journal of Molecular Sciences; Volume 23; Issue 3; Pages: 1754
International Journal of Molecular Sciences; Volume 23; Issue 3; Pages: 1754
Immune checkpoint therapy has shown great promise in the treatment of cancers with a high mutational burden, such as mismatch repair-deficient colorectal carcinoma (dMMR CRC). However, many patients fail to respond to immune checkpoint therapy. Using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0885d7454c7f83f7a630bb080e938174
https://pubmed.ncbi.nlm.nih.gov/35163675
https://pubmed.ncbi.nlm.nih.gov/35163675